{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T06:10:14Z","timestamp":1791267014144,"version":"4.1.0"},"reference-count":36,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2017,5,26]],"date-time":"2017-05-26T00:00:00Z","timestamp":1495756800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Sanofi Middle East","award":["DIREG_L_05534"],"award-info":[{"award-number":["DIREG_L_05534"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The stratification of outpatients on chemotherapy for breast, colorectal, lung, and ovarian cancers at risk of venous thromboembolism (VTE) remains an unmet clinical need. The derivation of a risk assessment model (RAM) for VTE in these patients was the aim of the study \u201cProspective Comparison of Methods for thromboembolic risk assessment with clinical Perceptions and AwareneSS in real life patients\u2013Cancer Associated Thrombosis\u201d (COMPASS\u2013CAT).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods<\/jats:title>\n                    <jats:p>The derivation cohort consisted of 1,023 outpatients. Patients on low molecular weight heparin (LMWH) thromboprophylaxis were excluded. Documented symptomatic VTE was the endpoint of the study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Patients had breast (61%), colorectal (17%), lung (13%), or ovarian cancer (8.6%) at localized (30%) or advanced stage (70%). In 64% of patients, cancer was diagnosed within the last 6 months prior to inclusion. Most of them were on chemotherapy when assessed. Symptomatic VTE occurred in 8.5% of patients. The COMPASS\u2013CAT RAM includes the following variables: (a) anthracycline or anti-hormonal therapy, (b) time since cancer diagnosis, (c) central venous catheter, (d) stage of cancer, (e) presence of cardiovascular risk factors, (f) recent hospitalization for acute medical illness, (g) personal history of VTE, and (h) platelet count. At 6 months, patients stratified at low\/intermediate and high-risk groups had VTE rates of 1.7% and 13.3%, respectively. The area under the curve of receiver operating characteristics analysis was 0.85. The sensitivity and specificity of the RAM were 88% and 52%, respectively. The negative and positive predictive values of the RAM were 98% and 13%, respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The COMPASS\u2013CAT RAM includes reliable and easily collected VTE risk predictors and, in contrast to the Khorana score, it is applicable after the initiation of anticancer treatment in patients with common solid tumors. Its robustness for stratification of patients at high and low\/intermediate VTE risk needs to be externally validated.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1634\/theoncologist.2016-0414","type":"journal-article","created":{"date-parts":[[2017,5,26]],"date-time":"2017-05-26T21:00:20Z","timestamp":1495832420000},"page":"1222-1231","source":"Crossref","is-referenced-by-count":250,"title":["A Predictive Score for Thrombosis Associated with Breast, Colorectal, Lung, or Ovarian Cancer: The Prospective COMPASS\u2013Cancer-Associated Thrombosis Study"],"prefix":"10.1093","volume":"22","author":[{"given":"Grigoris T.","family":"Gerotziafas","sequence":"first","affiliation":[{"name":"Cancer Biology and Therapeutics INSERM U938, Institut Universitaire de Canc\u00e9rologie (IUC), Facult\u00e9 de M\u00e9decine Pierre et Marie Curie, Universit\u00e9 Pierre et Marie Curie (UPMC), Sorbonne Universit\u00e9s, Paris, France"},{"name":"Service d'H\u00e9matologie Biologique H\u00f4pital Tenon, H\u00f4pitaux Universitaires Est Parisien, Assistance Publique H\u00f4pitaux de Paris, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Taher","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Hematology\/Oncology American University of Beirut, Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hikmat","family":"Abdel-Razeq","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine King Hussein Cancer Center, Amman, Jordan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Essam","family":"AboElnazar","sequence":"additional","affiliation":[{"name":"Surgery Department Umm Al-Qura University, Mecca, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex C.","family":"Spyropoulos","sequence":"additional","affiliation":[{"name":"Department of Medicine, Anticoagulation and Clinical Thrombosis Services Hofstra Northwell School of Medicine, Northwell Health System, Manhasset, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salem","family":"El Shemmari","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Kuwait Cancer Control Center, Kuwait City, Kuwait"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annette K.","family":"Larsen","sequence":"additional","affiliation":[{"name":"Cancer Biology and Therapeutics INSERM U938, Institut Universitaire de Canc\u00e9rologie (IUC), Facult\u00e9 de M\u00e9decine Pierre et Marie Curie, Universit\u00e9 Pierre et Marie Curie (UPMC), Sorbonne Universit\u00e9s, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ismail","family":"Elalamy","sequence":"additional","affiliation":[{"name":"Cancer Biology and Therapeutics INSERM U938, Institut Universitaire de Canc\u00e9rologie (IUC), Facult\u00e9 de M\u00e9decine Pierre et Marie Curie, Universit\u00e9 Pierre et Marie Curie (UPMC), Sorbonne Universit\u00e9s, Paris, France"},{"name":"Service d'H\u00e9matologie Biologique H\u00f4pital Tenon, H\u00f4pitaux Universitaires Est Parisien, Assistance Publique H\u00f4pitaux de Paris, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the COMPASS\u2013CAT Working Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2017,5,26]]},"reference":[{"key":"2021122508231682100_R1","author":"Lyman","year":"2013"},{"key":"2021122508231682100_R2","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1038\/bjc.2012.401","article-title":"Asymptomatic deep vein thrombosis and superficial vein thrombosis in ambulatory cancer patients: Impact on short-term survival","volume":"107","author":"Gary","year":"2012","journal-title":"Br J Cancer"},{"key":"2021122508231682100_R3","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1200\/JCO.2006.07.4393","article-title":"Incidence of venous thromboembolism and the impact on survival in breast cancer patients","volume":"25","author":"Chew","year":"2007","journal-title":"J Clin Oncol"},{"key":"2021122508231682100_R4","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1182\/blood-2015-01-625582","article-title":"When are breast cancer patients at highest risk of venous thromboembolism? A cohort study using English health care data","volume":"127","author":"Walker","year":"2016","journal-title":"Blood"},{"key":"2021122508231682100_R5","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/bjc.2015.406","article-title":"Colorectal cancer, comorbidity, and risk of venous thromboembolism: Assessment of biological interactions in a Danish nationwide cohort","volume":"114","author":"Ahern","year":"2016","journal-title":"Br J Cancer"},{"key":"2021122508231682100_R6","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1177\/0003319715614945","article-title":"Venous thromboembolism in patients diagnosed with lung cancer","volume":"67","author":"Salla","year":"2016","journal-title":"Angiology"},{"key":"2021122508231682100_R7","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/bju.13238","article-title":"Incidence and risk factors of venous thromboembolism after pelvic uro-oncologic surgery\u2014A single center experience","volume":"117","author":"Chen","year":"2016","journal-title":"BJU Int"},{"key":"2021122508231682100_R8","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.breast.2013.04.018","article-title":"Risk factors associated with venous thromboembolism in 49,028 mastectomy patients","volume":"22","author":"Tran","year":"2013","journal-title":"Breast"},{"key":"2021122508231682100_R9","doi-asserted-by":"crossref","first-page":"3466","DOI":"10.1200\/JCO.2011.35.5669","article-title":"High incidence of thromboembolic events in patients treated with cisplatin-based chemotherapy: A large retrospective analysis","volume":"29","author":"Moore","year":"2011","journal-title":"J Clin Oncol"},{"key":"2021122508231682100_R10","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.beha.2008.12.001","article-title":"Epidemiology of cancer-related venous thromboembolism","volume":"22","author":"Wun","year":"2009","journal-title":"Best Pract Res Clin Haematol"},{"key":"2021122508231682100_R11","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD006652.pub4","volume-title":"Parenteral anticoagulation in ambulatory patients with cancer","author":"Akl","year":"2014"},{"key":"2021122508231682100_R12","doi-asserted-by":"crossref","first-page":"e195S","DOI":"10.1378\/chest.11-2296","article-title":"Prevention of VTE in nonsurgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines","volume":"141","author":"Kahn","year":"2012","journal-title":"Chest"},{"key":"2021122508231682100_R13","first-page":"111","article-title":"Prevention and treatment of venous thromboembolism\u2014International Consensus Statement","volume":"32","author":"Nicolaides","year":"2013","journal-title":"Int Angiol"},{"key":"2021122508231682100_R14","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/jth.12071","article-title":"International clinical practice guidelines for the treatment and prophylaxis of thrombosis associated with central venous catheters in patients with cancer","volume":"11","author":"Debourdeau","year":"2013","journal-title":"J Thromb Haemost"},{"key":"2021122508231682100_R15","volume-title":"Di Nisio M, Porreca E, Otten HM","year":"2014"},{"key":"2021122508231682100_R16","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1200\/JCO.2014.59.7351","article-title":"Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update 2014","volume":"33","author":"Lyman","year":"2015","journal-title":"J Clin Oncol"},{"key":"2021122508231682100_R17","doi-asserted-by":"crossref","first-page":"4902","DOI":"10.1182\/blood-2007-10-116327","article-title":"Development and validation of a predictive model for chemotherapy-associated thrombosis","volume":"111","author":"Khorana","year":"2008","journal-title":"Blood"},{"key":"2021122508231682100_R18","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s11739-012-0784-y","article-title":"A modified Khorana risk assessment score for venous thromboembolism in cancer patients receiving chemotherapy: The Protecht score","volume":"7","author":"Verso","year":"2012","journal-title":"Intern Emerg Med"},{"key":"2021122508231682100_R19","doi-asserted-by":"crossref","first-page":"5377","DOI":"10.1182\/blood-2010-02-270116","article-title":"Prediction of venous thromboembolism in cancer patients","volume":"116","author":"Ay","year":"2010","journal-title":"Blood"},{"key":"2021122508231682100_R20","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1056\/NEJMoa1108898","article-title":"Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer","volume":"366","author":"Agnelli","year":"2012","journal-title":"N Engl J Med"},{"key":"2021122508231682100_R21","author":"George"},{"key":"2021122508231682100_R22","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1111\/jth.13378","article-title":"Predictors of active cancer thromboembolic outcomes: Validation of the Khorana score among patients with lung cancer","volume":"14","author":"Mansfield","year":"2016","journal-title":"J Thromb Haemost"},{"key":"2021122508231682100_R23","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1001\/archinte.164.9.963","article-title":"Risk factors for venous thromboembolism in hospitalized patients with acute medical illness: Analysis of the MEDENOX Study","volume":"164","author":"Alikhan","year":"2004","journal-title":"Arch Intern Med"},{"key":"2021122508231682100_R24","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/S0037-1963(01)90094-0","article-title":"Effective risk stratification of surgical and nonsurgical patients for venous thromboembolic disease","volume":"38","author":"Caprini","year":"2001","journal-title":"Semin Hematol"},{"key":"2021122508231682100_R25","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1111\/j.1538-7836.2011.04336.x","article-title":"The AVAIL ME Extension: A multinational Middle Eastern survey of venous thromboembolism risk and prophylaxis","volume":"9","author":"Mokhtari","year":"2011","journal-title":"J Thromb Haemost"},{"key":"2021122508231682100_R26","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/jth.12262","article-title":"Diagnostic and prognostic prediction models","volume":"11","author":"Hendriksen","year":"2013","journal-title":"J Thromb Haemost"},{"key":"2021122508231682100_R27","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4","article-title":"Multivariable prognostic models: Issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors","volume":"15","author":"Harrell","year":"1996","journal-title":"Stat Med"},{"key":"2021122508231682100_R28","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1016\/S0895-4356(96)00236-3","article-title":"A simulation study of the number of events per variable in logistic regression analysis","volume":"49","author":"Peduzzi","year":"1996","journal-title":"J Clin Epidemiol"},{"key":"2021122508231682100_R29","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1056\/NEJM198509263131306","article-title":"Clinical prediction rules: Applications and methodological standards","volume":"313","author":"Wasson","year":"1985","journal-title":"N Engl J Med"},{"key":"2021122508231682100_R30","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.thromres.2016.01.002","article-title":"Risk factors for incident venous thromboembolism in active cancer patients: A population based case-control study","volume":"139","author":"Ashrani","year":"2016","journal-title":"Thromb Res"},{"key":"2021122508231682100_R31","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1056\/NEJMoa1500964","article-title":"Intravascular complications of central venous catheterization by insertion site","volume":"373","author":"Parienti","year":"2015","journal-title":"N Engl J Med"},{"key":"2021122508231682100_R32","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jmv.2014.03.001","article-title":"Compliance with recommendations of clinical practice in the management of venous thromboembolism in cancer: The CARMEN study","volume":"39","author":"Sevestre","year":"2014","journal-title":"J Mal Vasc"},{"key":"2021122508231682100_R33","doi-asserted-by":"crossref","first-page":"405","DOI":"10.3109\/07357907.2015.1048871","article-title":"Deep vein thrombosis (DVT) and pulmonary embolism (PE): Awareness and prophylaxis practices reported by patients with cancer","volume":"33","author":"Aggarwal","year":"2015","journal-title":"Cancer Invest"},{"key":"2021122508231682100_R34","doi-asserted-by":"crossref","first-page":"S168","DOI":"10.1016\/S0049-3848(16)30118-9","article-title":"Clinical history of cancer patients with isolated distal deep vein thrombosis: A multicenter cohort study","volume":"140 suppl 1","author":"Dentali","year":"2016","journal-title":"Thromb Res"},{"key":"2021122508231682100_R35","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.thromres.2016.04.003","article-title":"Retrospective review on isolated distal deep vein thrombosis (IDDVT) - A benign entity or not?","volume":"142","author":"Ho","year":"2016","journal-title":"Thromb Res"},{"key":"2021122508231682100_R36","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.thromres.2014.03.033","article-title":"Two years outcome of isolated distal deep vein thrombosis","volume":"134","author":"Sartori","year":"2014","journal-title":"Thromb Res"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2016-0414","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2016-0414","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/22\/10\/1222\/41913258\/oncolo_22_10_1222.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/22\/10\/1222\/41913258\/oncolo_22_10_1222.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,25]],"date-time":"2021-12-25T03:24:23Z","timestamp":1640402663000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/22\/10\/1222\/6444576"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,26]]},"references-count":36,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2017,5,26]]},"published-print":{"date-parts":[[2017,10,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2016-0414","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2017,10,1]]},"published":{"date-parts":[[2017,5,26]]}}}